During a live event, Konstantinos Sdrimas, MD, asked participants what community oncologists should consider when referring ...

EBC-129 has been granted FDA fast track designation for the treatment of pancreatic ductal adenocarcinoma, paving the way for ...

Papaverine, an investigational drug shown to sensitise tumor cells to radiation therapy by blocking oxygen consumption in tumor cells in preclinical and ongoing clinical trials, is now being tested in ...

The FDA has granted clearance to the IND applications for both the therapeutic ( [ 225 Ac]Ac-AKY-1189) and imaging ( [ 64 ...

Toon Van Gorp, MD, PhD, discusses the rationale behind and the findings from the phase 3 MIRASOL trial of mirvetuximab soravtansine in patients with folate receptor α–positive, platinum-resistant ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Chandler H. Park, MD, and event participants looked at quality of life, tolerability, and rechallenging ...

This priority review designation for sevabertinib in previously treated HER2-mutant non–small cell lung cancer is supported by data from the phase 1/2 SOHO-01 study.

However, according to Aizer, many questions remain unanswered in the field of brain metastases, particularly concerning radiation treatment. While clinicians continually strive to improve radiation's ...

During a live event, Gary J. Schiller, MD, reviewed the diagnostics and characteristics of blastic plasmacytoid dendritic ...

A zanubrutinib, venetoclax, and obinutuzumab triplet achieved deep remissions and high undetectable measurable residual ...

Alexander Kenigsberg, MD, discusses a new option for treating prostate cancer: robotic high-intensity focused ultrasound.